

EFFICACY REVIEW

DATE: IN 5- 2-95 OUT 7-21-95

FILE OR REG. NO. 45729-E

PETITION OR EXP. PERMIT NO. _____

DATE DIV. RECEIVED April 11, 1995

DATE OF SUBMISSION April 6, 1995

DATE SUBMISSION ACCEPTED _____

TYPE PRODUCT(S): (I,)D, H, F, N, R, S _____

DATA ACCESSION NO(S) . 418377-05;D214855;S485544;Case#016299;AC:116

PRODUCT MGR. NO. 10-Keigwin/Sibold

PRODUCT NAME(S) De-Flea Shampoo Concentrate

COMPANY NAME Safe and Sure Products, Incorporated

SUBMISSION PURPOSE Provide performance data on "new" active ingredient (with history of use in auricular miticide) as toxicant to fleas in shampoo formulation.

CHEMICAL & FORMULATION Diocetyl sodium sulfosuccinate 12.0%
Undecylenic acid 2.0%
(7.8 lbs. per gal. net weight, dilutable)

CONCLUSIONS & RECOMMENDATIONS The data presented in EPA Accession (MRID) Number 418377-05, having been obtained from a standard kennel test meeting the requirements of § 95-9(a) (2) and (3) on p. 263 and the standard of § 95-9(b) (2) (i) on p. 264 of the Product Performance Guidelines, are adequate to demonstrate the ability of the combination of two "new" active ingredients to quickly reduce the population of the cat flea, Ctenocephalides felis, on dogs of varying hair length and texture following application of the subject product when diluted and used according to label directions. Since the product makes no residual claims but rather instructs use "... as often as needed...", it satisfies the requirements for a flea shampoo. However, the claim for ticks has not been satisfactorily supported and will require submission of minimal data on the effectiveness of the product against brown dog tick and/or American dog tick. This is necessary because we have no background on acaricidal properties of this combination of active ingredients. The names for the active ingredients used on the submitted label are not acceptable according to 40 CFR 156.10(g) (3). Use dioctyl sodium sulfosuccinate and undecylenic acid, not docusate sodium and hendecenoic acid, on the ingredient statement.

RL Vern L. McFarland, IRB

1
1